Cytoreductive surgery for ovarian cancer usually includes Supracolic omentectomy, sometimes with rectosigmoid resection (usually with primary reanastomosis) Radical peritoneal stripping Resection of diaphragmatic peritoneum or splenectomy Cytoreduction may be Complete: Cytoreduction to no grossly visible disease Optimal: Cytoreduction with residual disease that is ≤ 1 cm in maximum tumor diameter, as defined by the Gynecologic Oncology Group Suboptimal: Cytoreduction with any visible tumor nodules > 1 cm remaining Because cytoreduction is associated with increased survival, being able to predict when cytoreduction to no gross residual disease can be done is important, but doing so is difficult; there are no uniform criteria.